Kelly Davio

A newly published paper seeks to better explore the experiences of men with rheumatoid arthritis in the context of their lives, their masculine identity, and their ability to cope with the disease.

Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.

With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.

CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.

In a recent JAMA Viewpoint, Andrew Kolondy, MD, and Thomas R. Frieden, MD, MPH, called on the US federal government to take 10 steps to address the problem of opioid addiction.

A new study suggests that ultrasound technology could allow for the earlier detection of inflammation, and therefore earlier treatment of inflammatory diseases, in patients with early joint pain.

A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma.

On Monday, California Governor Jerry Brown (D) signed into law SB 17, which seeks to generate greater transparency concerning drug pricing.

Relieving pain and improving sleep may be key factors in decreasing the severity of rheumatoid arthritis (RA), according to a recent study’s findings.

CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.